Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 1, 2012, Pages 72-82

  Schreiter, Nils F ^a   Brenner, Winfried ^a   Nogami, Munenobu ^b   Buchert, Ralph ^a   Huppertz, Alexander ^a   Pape, Ulrich Frank ^a   Prasad, Vikas ^a   Hamm, Bernd ^a   Maurer, Martin H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Department of Radiology and Nuclear Medicine   (Japan)

Author keywords

111In DTPA octreotide scintigraphy; 68Ga DOTATOC PET CT; Cost evaluation

Indexed keywords

GALLIUM 68; PENTETREOTIDE IN 111; 111IN OCTREOTIDE, DTPA(0); 111IN-OCTREOTIDE, DTPA(0)-; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GA(III) DOTATOC; GA(III)-DOTATOC; OCTREOTIDE; ORGANOMETALLIC COMPOUND; PENTETIC ACID;

ADULT; AGED; ARTICLE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; COST BENEFIT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; SCINTIGRAPHY; SENSITIVITY ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WHOLE BODY SCINTISCANNING; COMPARATIVE STUDY; ECONOMICS; MIDDLE AGED; PATHOLOGY; SCINTISCANNING;

ADULT; AGED; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; PENTETIC ACID; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY;

EID: 84858778411     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1935-5     Document Type: Article

References (28)

1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97(4):934-59. (Pubitemid 36173145)
2. Klöppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009;90(2):162-6.
3. Rambaldi PF, Cuccurullo V, Briganti V, Mansi L. The present and future role of (111)In pentetreotide in the PET era. Q J Nucl Med Mol Imaging 2005;49(3):225-35. (Pubitemid 41569510)
4. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20(8):716-31. (Pubitemid 23284773)
5. Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010;37(7):1441-8.
6. Kowalski J, Henze M, Schuhmacher J, Mäcke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5(1):42-8. (Pubitemid 36596544)
7. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34(10):1617-26. (Pubitemid 47476920)
8. Hartmann H, Zöphel K, Freudenberg R, Oehme L, Andreeff M, Wunderlich G, et al. Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations. Nuklearmedizin 2009;48(5):201-7.
9. Gocke P, Debatin JF, Dürselen LF. Process management and controlling in diagnostic radiology in the hospital. Radiologe 2002;42(5):332-43. (Pubitemid 36068267)
10. Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, et al. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med 2001;42(7):1134-8. (Pubitemid 32595318)
11. Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med 2007;48(10):1741-8. (Pubitemid 47572722)
12. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26(18):3063-72.
13. Kocha W, Maroun J, Kennecke H, Law C, Metrakos P, Ouellet JF, et al. Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuro-endocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol 2010;17(3):49-64.
14. Janson ET, Sørbye H, Welin S, Federspiel B, Grønbaek H, Hellman P, et al. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol 2010;49(6):740-56.
15. Arnold R, Chen YJ, Costa F, Falconi M, Gross D, Grossman AB, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 2009;90(2):227-33.
16. Sundin A, Vullierme MP, Kaltsas G, Plöckinger U, Mallorca Consensus Conference participants, European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009;90(2):167-83.
17. Plathow C, Walz M, Lichy MP, Aschoff P, Pfannenberg C, Bock H, et al. Cost considerations for whole-body MRI and PET/CT as part of oncologic staging. Radiologe 2008;48(4):384-96. (Pubitemid 351720456)
18. Schmidt GP, Haug AR, Schoenberg SO, Reiser MF. Whole-body MRI and PET-CT in the management of cancer patients. Eur Radiol 2006;16(6):1216-25. (Pubitemid 43834707)
19. Baum RP, Prasad V, Hörsch D. Molekulare Bildgebung neuroendokriner Tumoren mit 68Ga-markierten Peptiden (Somatostatinrezeptor-PET/CT). Nuklearmediziner 2009;32:115-30.
20. Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989;1(8632):242-4.
21. Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, de Jong M, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992;33(5):652-8.
22. Smith-Jones PM, Stolz B, Bruns C, Albert R, Reist HW, Fridrich R, et al. Gallium-67/gallium-68-[DFO]-octreotide-a potentialradiopharmaceutical for PET imaging of somatostatin receptorpositive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. J Nucl Med 1994;35(2):317-25. (Pubitemid 24048322)
23. de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0, d-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24(4):368-71. (Pubitemid 27183039)
24. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998;351(9100):417-8. (Pubitemid 28064170)
25. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34(7):982-93. (Pubitemid 46919547)
26. Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A, et al. Impact of multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology 2010;91(1):101-9.
27. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48(4):508-18. (Pubitemid 47571404)
28. Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, et al. (68)Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with (111)In-DTPA-octreotide (OctreoScan®). Mol Imaging Biol 2011;13(3):583-93.